Zentalis Pharmaceuticals Inc. Common Stock (ZNTL)
Stock · NASDAQ · Health Care
$2.15as of 10/16/2026
Price chart
Active signals
ZNTL Signal Track Record
How signals performed across all stocks →What ZNTL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -1.8% | 47% | September 29, 2026 |
| Bollinger Band BreakdownActive now | 18 | -4.2% | 33% | September 15, 2026 |
| Bollinger Band Breakout | 18 | -8.8% | 28% | June 29, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -20.8% | 25% | October 10, 2025 |
| Any 20-session window (baseline) | -4.8% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in sol…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 106
- Website
- www.zentalis.com/
Fundamentals
- 1-day range
- $2.1$2.28
- Market cap
- $355.93M
- P/E (trailing)
- —
- P/E (forward)
- -1.20
- EPS (trailing)
- $-1.91
- Dividend yield
- —
- Beta
- 1.92
- Avg. volume
- 1.17M
How Zentalis Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 26, 2025 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Zentalis Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ZNTLZentalis Pharmaceuticals Inc. Common Stock$2.13▼ 4.91%Market cap $355.93MP/E —$1.21$6.95
- NATRNature's Sunshine Products Inc. Common Stock$12.64▲ 0.00%Market cap $357.68MP/E 12.66$12.8$28.14
- LYELLyell Immunopharma Inc. Common Stock$8.12▼ 0.85%Market cap $348.21MP/E —$7.2$45
- DMACDiaMedica Therapeutics Inc. Common Stock$7.57▼ 5.85%Market cap $364.79MP/E —$5.25$10.42
- PRLDPrelude Therapeutics Incorporated Common Stock$3.26▼ 1.81%Market cap $372.74MP/E —$1.16$6.83
- CATXPerspective Therapeutics Inc. Common Stock$2.17▼ 7.26%Market cap $338.72MP/E —$1.96$6.16
- UPBUpstream Bio Inc. Common Stock$2.76▼ 18.10%Market cap $373.87MP/E —$3.29$33.68
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ZNTL Zentalis Pharmaceuticals Inc. Common Stock | $355.93M | — | $2.13 | ▼ 4.91% | $1.21$6.95 |
| NATR Nature's Sunshine Products Inc. Common Stock | $357.68M | 12.66 | $12.64 | ▲ 0.00% | $12.8$28.14 |
| LYEL Lyell Immunopharma Inc. Common Stock | $348.21M | — | $8.12 | ▼ 0.85% | $7.2$45 |
| DMAC DiaMedica Therapeutics Inc. Common Stock | $364.79M | — | $7.57 | ▼ 5.85% | $5.25$10.42 |
| PRLD Prelude Therapeutics Incorporated Common Stock | $372.74M | — | $3.26 | ▼ 1.81% | $1.16$6.83 |
| CATX Perspective Therapeutics Inc. Common Stock | $338.72M | — | $2.17 | ▼ 7.26% | $1.96$6.16 |
| UPB Upstream Bio Inc. Common Stock | $373.87M | — | $2.76 | ▼ 18.10% | $3.29$33.68 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8benzinga · 10/5/2026
- Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform RatingYahoo · 10/5/2026
- Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8Benzinga · 10/5/2026
- This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak SalesBenzinga · 9/16/2026
- William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform RatingBenzinga · 9/16/2026
- Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/14/2026
Insider Activity
Insider Actions →- Ingmar Bruns · September 30, 2026 · Grant9.7K @ $2.18
- WALTERS GROUP · August 14, 2026 · Buy4.33M @ $3.5
- Scott Dunseth Myers · June 16, 2026 · Grant57.1K
- Shannon Campbell · May 26, 2026 · Grant114.2K
Institutional Ownership
March 31, 2026
- Total shares held
- 43.23M
- Total value held
- $92.70M
- Institutional holders
- 97
- Unknown4.03M
- Unknown3.95M
- Unknown2.96M
- Unknown2.85M
- Unknown2.31M
- Unknown1.94M
- Unknown1.76M
- Unknown1.48M
- Unknown1.41M
- Unknown1.32M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Leerink Partners initiates coverage of Zentalis at Outperform
Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.
Leerink Partners initiates coverage of Zentalis at Outperform. Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.